STC BIOLOGICS, INC — Department of Health and Human Services SBIR Phase I: 102

Description

DESCRIPTION provided by applicant Although targeted therapies have been developed to treat cancers with well elucidated molecular pathways these therapies still remain ineffective as innate or acquired resistance often limits their ability to produce initial or durable responses Patients with colorectal cancer CRC that harbor a BRAF mutation have the poorest outcomes of all CRC patients and are resistant to EGFR and BRAF directed therapies as single agents such as cetuximab and vemurafenib Ligands have significant responsibility for fueling oncogenic pathways yet there are few ligand targeted therapies in clinical development We developed a novel multi targeting ligand trap LC directed against ligands to the ERBB HER family of receptor tyrosine kinases RTKs LC binds to a wide spectrum of ERBB ligands including TGFa betacellulin BTC and heregulin HRG NRG and prevents ligand binding to multiple ERBB receptors including EGFR ERBB HER and ERBB HER Given its unique ability to capture a wide spectrum of ligands LC may exhibit an improved activity over agents that only target EGFR such as cetuximab because it may prevent MAP Kinase MAPK signaling by EGFR ERBB heterodimers and PI K AKT signaling by ERBB ERBB heterodimers In fact HRG upregulation and high levels of phospho AKT have been correlated with resistance to cetuximab Furthermore in BRAF mutant CRC cells treated with vemurafenib the MAPK AKT pathway is still active despite mutant BRAF inhibition because of ligand dependent feedback activation of EGFR Based on these findings our hypothesis is that a combination of LC with vemurafenib should be able to overcome EGFR ERBB driven MAPK and PI K AKT activation In this proposal we plan to demonstrate that LC in combination with vemurafenib prevents feedback activation of EGFR that occurs in BRAF mutant CRC cells treated with vemurafenib and that the combination results in greater tumor growth inhibition in BRAF mutant CRC xenografts than a combination of cetuximab with vemurafenib This work has the potential to advance treatment options for CRC patients with BRAF mutations who derive little benefit from current treatment regimens especially compared with other molecular subgroups of CRC This proposal introduces a novel ligand directed therapeutic that can be explored as a single agent or in rational combination with other targeted therapies or chemotherapies This work should also help to validate the multi targeting ligand capture platform for additional ligand targets replete with development and commercialization opportunities PUBLIC HEALTH RELEVANCE Many targeted therapies still remain ineffective as innate or acquired resistance often limits their ability to produce initial or durable responses The goal of this grant proposal is to develop a therapy that will help to overcome this limitation